FROM October 1 2016 Australia's first interleukin-17A (IL- 17A) inhibitor Cosentyx (secukinumab) from Novartis will be reimbursed on the Pharmaceutical Benefits Scheme for the treatment of two chronic, systemic inflammatory diseases: ankylosing spondylitis and severe psoriatic arthritis under specific conditions.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Oct 16
